Beniag

Executive Summary

Beniag GmbH is a Munich-based biotechnology company founded in 2018 that specializes in developing novel transfection systems using membrane fusion technology. Its flagship Fuse-It product line enables rapid, highly efficient delivery of a wide range of organic biomolecules into living cells, independent of biological cellular processes. This technology addresses key limitations of traditional transfection methods, such as low efficiency and cell toxicity, offering potential applications in gene therapy, cell engineering, and drug discovery. As a private company, Beniag operates in the competitive drug delivery space but differentiates itself through a fusion-based approach that promises faster and more versatile molecular incorporation. The company has not disclosed funding or valuation details, but its focus on a critical enabling technology positions it as a potential partner for therapeutic developers seeking improved delivery solutions. With a solid technological foundation and a niche in transfection, Beniag is poised to capture value in the expanding cell and gene therapy market.

Upcoming Catalysts (preview)

• Q3 2026Partnership with a major pharma or biotech for Fuse-IT licensing40% success
• Q4 2026Series A or B funding round to scale operations50% success
• Q2 2026Publication of preclinical data demonstrating in vivo efficacy60% success